Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
Identifieur interne : 000771 ( PubMed/Corpus ); précédent : 000770; suivant : 000772Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
Auteurs : Natasja St Hr Gudmann ; Peter Junker ; Pernille Juhl ; Christian Schneider Thudium ; Anne Sofie Siebuhr ; Inger Byrjalsen ; Morten Asser Karsdal ; Anne Christine Bay-JensenSource :
- Clinical and experimental rheumatology [ 0392-856X ]
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (blood), Arthritis, Rheumatoid (diagnostic imaging), Arthritis, Rheumatoid (drug therapy), Biomarkers (blood), Collagen Type IV (blood), Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Methotrexate (therapeutic use), Middle Aged, Severity of Illness Index, Synovial Membrane (diagnostic imaging), Synovial Membrane (drug effects), Synovial Membrane (metabolism), Treatment Outcome.
- MESH :
- chemical , blood : Biomarkers, Collagen Type IV.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Methotrexate.
- blood : Arthritis, Rheumatoid.
- diagnostic imaging : Arthritis, Rheumatoid, Synovial Membrane.
- drug effects : Synovial Membrane.
- drug therapy : Arthritis, Rheumatoid.
- metabolism : Synovial Membrane.
- Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome.
Abstract
The expanding spectrum of targeted therapies for rheumatoid arthritis (RA) implies a need for development of precision tools for disease assessment reflecting pathobiologic processes. Type IV collagen is an abundant protein of basement membranes, but is also present in the intercellular matrix of the synovial lining layer. We aimed to investigate the association of type IV collagen turnover with RA disease activity, response to IL-6 inhibition and radiographic progression.
PubMed: 29745884
Links to Exploration step
pubmed:29745884Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.</title><author><name sortKey="Gudmann, Natasja St Hr" sort="Gudmann, Natasja St Hr" uniqKey="Gudmann N" first="Natasja St Hr" last="Gudmann">Natasja St Hr Gudmann</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. nsg@nordicbio.com.</nlm:affiliation></affiliation></author><author><name sortKey="Junker, Peter" sort="Junker, Peter" uniqKey="Junker P" first="Peter" last="Junker">Peter Junker</name><affiliation><nlm:affiliation>Department of Rheumatology, Odense University Hospital, Odense, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Juhl, Pernille" sort="Juhl, Pernille" uniqKey="Juhl P" first="Pernille" last="Juhl">Pernille Juhl</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Thudium, Christian Schneider" sort="Thudium, Christian Schneider" uniqKey="Thudium C" first="Christian Schneider" last="Thudium">Christian Schneider Thudium</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Siebuhr, Anne Sofie" sort="Siebuhr, Anne Sofie" uniqKey="Siebuhr A" first="Anne Sofie" last="Siebuhr">Anne Sofie Siebuhr</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Byrjalsen, Inger" sort="Byrjalsen, Inger" uniqKey="Byrjalsen I" first="Inger" last="Byrjalsen">Inger Byrjalsen</name><affiliation><nlm:affiliation>Clinical Development, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Karsdal, Morten Asser" sort="Karsdal, Morten Asser" uniqKey="Karsdal M" first="Morten Asser" last="Karsdal">Morten Asser Karsdal</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Bay Jensen, Anne Christine" sort="Bay Jensen, Anne Christine" uniqKey="Bay Jensen A" first="Anne Christine" last="Bay-Jensen">Anne Christine Bay-Jensen</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2018 Sep-Oct</MedlineDate></PubDate></date><idno type="RBID">pubmed:29745884</idno><idno type="pmid">29745884</idno><idno type="wicri:Area/PubMed/Corpus">000771</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000771</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.</title><author><name sortKey="Gudmann, Natasja St Hr" sort="Gudmann, Natasja St Hr" uniqKey="Gudmann N" first="Natasja St Hr" last="Gudmann">Natasja St Hr Gudmann</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. nsg@nordicbio.com.</nlm:affiliation></affiliation></author><author><name sortKey="Junker, Peter" sort="Junker, Peter" uniqKey="Junker P" first="Peter" last="Junker">Peter Junker</name><affiliation><nlm:affiliation>Department of Rheumatology, Odense University Hospital, Odense, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Juhl, Pernille" sort="Juhl, Pernille" uniqKey="Juhl P" first="Pernille" last="Juhl">Pernille Juhl</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Thudium, Christian Schneider" sort="Thudium, Christian Schneider" uniqKey="Thudium C" first="Christian Schneider" last="Thudium">Christian Schneider Thudium</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Siebuhr, Anne Sofie" sort="Siebuhr, Anne Sofie" uniqKey="Siebuhr A" first="Anne Sofie" last="Siebuhr">Anne Sofie Siebuhr</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Byrjalsen, Inger" sort="Byrjalsen, Inger" uniqKey="Byrjalsen I" first="Inger" last="Byrjalsen">Inger Byrjalsen</name><affiliation><nlm:affiliation>Clinical Development, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Karsdal, Morten Asser" sort="Karsdal, Morten Asser" uniqKey="Karsdal M" first="Morten Asser" last="Karsdal">Morten Asser Karsdal</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Bay Jensen, Anne Christine" sort="Bay Jensen, Anne Christine" uniqKey="Bay Jensen A" first="Anne Christine" last="Bay-Jensen">Anne Christine Bay-Jensen</name><affiliation><nlm:affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical and experimental rheumatology</title><idno type="ISSN">0392-856X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (diagnostic imaging)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Biomarkers (blood)</term><term>Collagen Type IV (blood)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Synovial Membrane (diagnostic imaging)</term><term>Synovial Membrane (drug effects)</term><term>Synovial Membrane (metabolism)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Collagen Type IV</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovial Membrane</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Synovial Membrane</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Synovial Membrane</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The expanding spectrum of targeted therapies for rheumatoid arthritis (RA) implies a need for development of precision tools for disease assessment reflecting pathobiologic processes. Type IV collagen is an abundant protein of basement membranes, but is also present in the intercellular matrix of the synovial lining layer. We aimed to investigate the association of type IV collagen turnover with RA disease activity, response to IL-6 inhibition and radiographic progression.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29745884</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0392-856X</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>5</Issue><PubDate><MedlineDate>2018 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Clinical and experimental rheumatology</Title><ISOAbbreviation>Clin. Exp. Rheumatol.</ISOAbbreviation></Journal><ArticleTitle>Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.</ArticleTitle><Pagination><MedlinePgn>829-835</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The expanding spectrum of targeted therapies for rheumatoid arthritis (RA) implies a need for development of precision tools for disease assessment reflecting pathobiologic processes. Type IV collagen is an abundant protein of basement membranes, but is also present in the intercellular matrix of the synovial lining layer. We aimed to investigate the association of type IV collagen turnover with RA disease activity, response to IL-6 inhibition and radiographic progression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">C4M, a serologic marker of type IV collagen metabolism, was measured at baseline and at follow-up in serum samples of RA patients participating in the phase III studies LITHE (n=687) and RADIATE (n=217). Both were double-blinded, placebo-controlled clinical trials testing the safety and efficacy of 4 and 8 mg/kg tocilizumab (TCZ) in combination with methotrexate (MTX) vs. MTX plus placebo. Associations with disease activity, radiographic severity and ACR response were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline C4M correlated significantly with clinical disease parameters in both study populations, including DAS28, HAQ score and VASpain (all p<0.00001). C4M at baseline correlated significantly with change in JSN (p=0.001) and Sharp score (p=0.00002) at 52 weeks. TCZ lowered C4M by 11-40% in a dose dependent manner. The likelihood of achieving an ACR20 response by week 16 was associated with C4M suppression exceeding the median decrease at week 4 (p<0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Type IV collagen remodelling was associated with disease activity and radiographic progression in RA and was persistently and dose-dependently suppressed by TCZ. These findings indicate that C4M may serve as a plausible biologic marker of destructive synovitis growth in RA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gudmann</LastName><ForeName>Natasja Stæhr</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. nsg@nordicbio.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junker</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juhl</LastName><ForeName>Pernille</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thudium</LastName><ForeName>Christian Schneider</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siebuhr</LastName><ForeName>Anne Sofie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrjalsen</LastName><ForeName>Inger</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Clinical Development, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karsdal</LastName><ForeName>Morten Asser</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bay-Jensen</LastName><ForeName>Anne Christine</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Rheumatol</MedlineTA><NlmUniqueID>8308521</NlmUniqueID><ISSNLinking>0392-856X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024141">Collagen Type IV</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024141" MajorTopicYN="N">Collagen Type IV</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013583" MajorTopicYN="N">Synovial Membrane</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>01</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29745884</ArticleId><ArticleId IdType="pii">12293</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000771 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000771 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29745884
|texte= Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29745884" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |